 |
|
Plasma Carnitine DeficiencyClinical Observations in 51 Pediatric Patients
Susan C. Winter, MD;
Steven Szabo-Aczel, MD;
Cynthia J. R. Curry, MD;
H. Terry Hutchinson, MD;
Rebecca Hogue;
Austin Shug, PhD
Am J Dis Child. 1987;141(6):660-665.
Abstract
• We studied the clinical spectrum associated with secondary plasma carnitine deficiency in 51 pediatric patients. Forty-three patients had total plasma carnitine values below 20 µmol/L and an additional eight patients had total values above 20 µmol/L but had low free plasma carnitine levels. The clinical presentation in the patients with total plasma carnitine deficiency included hypotonia (34 of 43), failure to thrive (27 of 43), recurrent infections (27 of 43), encephalopathy (six of 43), nonketotic hypoglycemia (seven of 43), and cardiomyopathy (nine of 43). Of the eight patients with low free and elevated esterified carnitine levels, the signs and symptoms at presentation included hypotonia (six of eight), recurrent infections (six of eight), failure to thrive (six of eight), encephalopathy (three of eight), nonketotic hypoglycemia (one of eight), and cardiomyopathy (one of eight). All patients were treated with L-carnitine. Treatment time varied from one month to 24 months (average, four months). A subjective improvement in muscle tone was seen in 24 of 38 patients, 22 of 33 patients showed acceleration of incremental growth, and infection frequency appeared to decrease in 18 of 33 patients. After therapy, the echocardiograms of all patients with cardiomyopathy normalized. There were no further hypoglycemic episodes. Of the nine patients with encephalopathy, eight showed improvement in their mental status. Three patients died of complications of their primary disorder. In our experience, secondary plasma carnitine deficiency is a common pediatric finding. The presence of failure to thrive, recurrent infections, hypotonia, encephalopathy, cardiomyopathy, or nonketotic hypoglycemia requires investigation of carnitine status.
(AJDC 1987;141:660-665)
Author Affiliations
From the Valley Children's Hospital, Fresno, Calif (Drs Winter, Szabo-Aczel, Curry, and Hutchinson and Ms Hogue); and the Veterans Administration Hospital, Madison, Wis (Dr Shug).
Footnotes
Accepted for publication Sept 16, 1986.
Reprint requests to Medical Genetics, Valley Children's Hospital, Fresno, CA 93703 (Dr Winter).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Use of Carnitine in Pediatric Nutrition
Crill and Helms
Nutr Clin Pract 2007;22:204-213.
ABSTRACT
| FULL TEXT
Gender and age differences in plasma carnitine, muscle strength, and exercise tolerance in haemodialysis patients
Constantin-Teodosiu et al.
Nephrol Dial Transplant 2002;17:1808-1813.
ABSTRACT
| FULL TEXT
Primary and Secondary Carnitine Deficiency Syndromes
Pons and De Vivo
J Child Neurol 1995;10:2S8-2S24.
ABSTRACT
The Role of L-Carnitine in Pediatric Cardiomyopathy
Winter et al.
J Child Neurol 1995;10:2S45-2S51.
ABSTRACT
A Child With Valproic Acid-Associated Carnitine Deficiency and Carnitine-Responsive Cardiac Dysfunction
Bratton et al.
J Child Neurol 1992;7:413-416.
ABSTRACT
|
